If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest: solid tumour
All Signature testsEvery panel compared, side by sideSignature STb33 genes from a blood drawSignature STb O118 genes from blood, including fusionsSignature STb O+523 genes, with TMB, MSI and pharmacogenomicsSignature STt OComprehensive profiling from a tissue blockTest: blood cancer
Signature BML+Myeloid, 600+ genes, with MDS and MPN overlapSignature BLL+Lymphoid, 600+ genes, with Philadelphia-like detectionSignature CustomDesigned around one question when neither family fitsMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillance for solid tumoursClear BloodResidual disease surveillance after blood cancer treatmentProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedJourneysFour composites showing how a decision gets madeCase studiesNine situations and the test that fits eachFAQThe questions we are asked mostCancer Dictionary · Blood and lymphatic
Classical Hodgkin lymphoma is defined by a rare malignant cell sitting in a large inflammatory background, which is why an adequate biopsy matters so much. Cure rates are high even in advanced disease, so the research effort is largely directed at reducing long-term harm rather than at increasing intensity. Response assessment partway through treatment is used to adapt what follows.
Also called Hodgkin disease, Classical Hodgkin lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma.
Start here
Hodgkin lymphoma is one of the most curable cancers there is, which turns the central question from whether treatment will work into how little treatment is enough to keep it working.
Classical Hodgkin lymphoma is defined by a rare malignant cell sitting in a large inflammatory background, which is why an adequate biopsy matters so much. Cure rates are high even in advanced disease, so the research effort is largely directed at reducing long-term harm rather than at increasing intensity. Response assessment partway through treatment is used to adapt what follows.
Before any molecular question
Usually established first: the histological subtype, the stage, and whether there are B symptoms. Because most patients are young and most will be cured, the long-term consequences of treatment are part of the decision from the beginning rather than an afterthought.
Usually already established
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Classical Hodgkin lymphoma
The large majority. Defined by Reed-Sternberg cells in an inflammatory background, and the subtype most of the literature refers to.
Nodular lymphocyte-predominant
A biologically distinct entity that behaves more like an indolent B-cell lymphoma and is managed differently. Getting this distinction right changes the whole plan.
Early-stage, favourable
Where de-escalation research is most active, because the question is how little treatment preserves the cure rate.
Advanced-stage
Still highly curable. Interim response assessment is used to adapt what follows.
Relapsed or refractory
Where immune approaches and antibody-drug conjugates dominate, and where cure remains a realistic goal rather than a remote one.
What is discussed
Hodgkin lymphoma is unusual in that the malignant cells are a small minority of what is in the biopsy, which makes conventional sequencing technically difficult. Alterations of chromosome 9p24.1 affecting PD-L1 and PD-L2 are near-universal in classical disease and explain why it is one of the most immune-responsive cancers known. CD30 expression is essentially defining and is the target of an established antibody-drug conjugate class. Epstein-Barr virus is present in a proportion of cases. Genomic profiling of the tumour cells themselves is largely a research activity; ctDNA is proving a more practical route to the genome than the biopsy is.
CD30
Essentially defining in classical disease, and a therapeutic target rather than only a diagnostic marker.
9p24.1 / PD-L1 and PD-L2
Near-universal alteration, and the reason this cancer responds to immune approaches so well.
CD20
Relevant in nodular lymphocyte-predominant disease rather than classical.
EBV
Present in a proportion of cases, with differing frequency by age and region.
ctDNA
Under study, and unusually useful here because the malignant cells are so sparse in tissue.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
What is tested, and from what
An excisional biopsy is strongly preferred. A fine needle aspirate is usually inadequate, because the malignant cells are rare in a background of normal immune cells and the diagnosis depends on seeing that architecture. Immunohistochemistry establishes the diagnosis and the subtype. Comprehensive genomic profiling is not routine, and where the genome is being interrogated, ctDNA is often the more informative sample than the biopsy.
Familial clustering is described and the risk to a sibling is measurably raised, but no single high-penetrance gene explains most cases and germline testing is not part of the routine pathway. Inherited immunodeficiency is relevant in unusual presentations.
Cancer genetics and hereditary riskctDNA is a particularly good fit for this disease, precisely because the tumour cells are so sparse in tissue that plasma can be a better window on the genome than a biopsy. It is under study for response assessment and for detecting relapse.
More on ctDNA monitoringThe timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
What shapes eligibility
Much of the trial activity is de-escalation: giving less treatment, or omitting radiation, while holding the cure rate. That is an unusual research aim and a reason to look at trials early rather than only at relapse.
| Term | What it means |
|---|---|
| Reed-Sternberg cell | The characteristic malignant cell of classical Hodgkin lymphoma. Rare within the biopsy, which is why an adequate sample matters. |
| B symptoms | Fever, drenching night sweats and unexplained weight loss. Part of staging. |
| Interim response assessment | A scan partway through treatment, used to decide what the rest of treatment should be. |
| De-escalation | Reducing treatment to lower long-term harm while preserving the cure rate. |
| Late effects | Health consequences appearing years or decades after treatment. Central to decisions in a young, curable population. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal